A Study of the Safety, Tolerability and Pharmacokinetics of ALN-TTR02 in Japanese Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

March 31, 2014

Study Completion Date

June 30, 2014

Conditions

Transthyretin (TTR)-Mediated Amyloidosis

Interventions

DRUG

patisiran (ALN-TTR02)

Ascending doses administered by intravenous (IV) infusion

DRUG

Sterile Normal Saline (0.9% NaCl)

Calculated volume to match active comparator

Trial Locations (1)

Clinical Site, London